India-US dispute over patents on dasatinib, a drug to treat leukemia
Channel: KEIWashDC
Date: 2014-10-23

Elizabeth Rajasingh of KEI talks about the efforts of the US government to pressure India, in order to block a compulsory license on patents on the cancer drug dasatinib.   Dasatinib, which is sold under the trade name Sprycel by BMS, treats certain fairly rare types of leukemia, and is used for patients who have developed resistance to imatinib (sold by Novartis as Gleevec).